Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* FEV1 between 20 and 60% predicted after having received 5 mg of albuterol and 0.5 mg of atrovent as nebulized standard of care therapy~* Male or female between the ages of 18 and 45~* Asthma diagnosed by a physician and present for at least 6 months~* oxygen saturation greater or equal to 90% on room air~* Non smoker or \< 10 pack-year history~* No other cause for wheezing/sob as determined by the treating physician~Exclusion Criteria:~* Clinical evidence or history of hepatic, renal, cardiovascular, GI, endocrine, metabolic or CNS disease which might interfere with the conduct of the study~* Acute respiratory failure or other significant pathology of the pulmonary system~* Female subjects who are pregnant or lactating~* Currently receiving therapy for a psychiatric disorder~* Subjects with a known sensitivity to formoterol (racemic or RR) or albuterol (racemic or lev)~* History of hospitalization for asthma within 2 months or treatment for acute asthma in an ED within 2 weeks of study entry~* Past or current use of disallowed medications~* Participation in an investigational study within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Arformoterol 3 doses (Type: EXPERIMENTAL): None
- Arformoterol 1 dose, placebo 2 doses (Type: EXPERIMENTAL): None
- Levalbuterol 3 doses (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).